Denmark is one of Europe’s most efficient clinical trial environments. With a population of approximately 5.9 million and a highly digitalised, universal healthcare system, Denmark consistently delivers among the fastest regulatory approval timelines in the EU while maintaining rigorous scientific and ethical standards. The country is particularly distinguished by its unique national health registries, which enable powerful data linkage and make Denmark exceptionally well suited for registry-based trials and real-world evidence (RWE) studies.
The Danish trial landscape is dominated by four university hospitals – Rigshospitalet, Aarhus University Hospital, Odense University Hospital, and Herlev Hospital – all of which maintain active research programmes in oncology, cardiovascular medicine, diabetes, and rare diseases. Danish investigators are internationally oriented, research-active, and fully comfortable with English-language trial conduct.
Denmark’s primary limitations are its small patient population and high costs driven by Scandinavian wage levels. It is not a natural primary enrolment country for large Phase III trials needing hundreds of patients, but as a quality site in a multinational programme – particularly one that benefits from registry linkage or Danish epidemiological data – Denmark adds exceptional value.
| Metric | Denmark |
| Competent Authority | Danish Medicines Agency (DKMA / Lægemiddelstyrelsen) |
| Ethics Review | National Committee on Health Research Ethics (NVK) and regional committees |
| Approval Timeline | ~30–45 days (one of fastest in EU) |
| Population | ~5.9 million |
| Strengths | Cardiovascular, oncology, diabetes, rare diseases; exceptional registry infrastructure |
Denmark is chosen for its quality, speed, and data infrastructure rather than its scale. Sponsors select Denmark when:
Denmark is not the right choice for sponsors who need to minimise per-patient costs or who require large patient volumes from a single country. Its value is in precision and quality, not throughput.
Denmark fully implements the EU Clinical Trials Regulation (EU CTR, Regulation EU 536/2014) and processes all interventional clinical trial applications via CTIS. The national competent authority is the Danish Medicines Agency (DKMA, Lægemiddelstyrelsen).
The ethics review system involves the National Committee on Health Research Ethics (NVK) and regional ethics committees. The NVK coordinates ethics review at the national level, while regional committees handle site-specific aspects. Denmark’s ethics review process is well-organised and predictable.
Denmark’s national CPR (Civil Person Register) system assigns a unique identifier to every resident, enabling linkage across the Danish Health Data Authority’s extensive registry network. Sponsors planning registry-linked trial endpoints or long-term follow-up studies should engage with Danish data access processes early, as these require separate approval from the Danish Health Data Authority.
Denmark is one of the fastest EU countries for clinical trial approval. For a well-prepared CTIS dossier, sponsors should plan for the following:
| Step | Estimated Timeline |
|---|---|
| CTIS submission and validation | 1–5 working days |
| DKMA Part I assessment | ~30–45 days |
| Ethics Committee Part II assessment | ~30–45 days (parallel) |
| RFI response period (if applicable) | 12–31 days (clock stopped) |
| Site contract and budget negotiation | 6–10 weeks |
| Estimated total from submission to first patient | ~3–5 months |
Denmark’s speed advantage is consistent and well-recognised in the industry. Site contracting at Danish university hospitals is also generally efficient. Rigshospitalet and Aarhus University Hospital have dedicated research contract offices that are familiar with international sponsor requirements.
Denmark’s four major university hospital networks are the foundation of its clinical trial activity:
Investigator availability is generally good, though competition from multiple simultaneous international trials means early engagement is important. Danish investigators are highly experienced in GCP and international trial conduct.
Denmark’s universal, publicly funded healthcare system (Sygehusvæsenet) means that essentially all Danes receive care through one of the regional hospital networks. This creates a highly centralised patient flow that facilitates identification of eligible participants at the major trial sites. For common diseases, Danish sites enrol reliably if the indication is well matched to their patient population.
The CPR registry system means that Danish investigators can cross-reference patient populations against disease registries to pre-identify potential candidates systematically. For rare diseases, Denmark’s registry linkage allows identification of essentially all confirmed patients in the country, making Denmark disproportionately productive relative to its size for rare disease programmes. Absolute numbers are still limited by population size.
Denmark’s start-up is among the fastest in Europe when considering both the regulatory phase and site contracting. The following reflects typical ranges:
| Activity | Estimated Duration |
|---|---|
| Regulatory and ethics approval (CTIS) | 30–45 days |
| Site contract and budget negotiation | 4–10 weeks |
| Site initiation visit and staff training | 2–3 weeks |
| Data access approval (if registry linkage) | 8–16 weeks (parallel track) |
| First patient screened | ~3–5 months from submission |
Sponsors planning registry-linked studies should initiate the data access application to the Danish Health Data Authority in parallel with the CTIS submission, as this process runs on a separate timeline and can become a rate-limiting step if not managed proactively.
Denmark is one of the most expensive countries in Europe for clinical research. Scandinavian salary levels for investigators, research nurses, and coordinators are significantly higher than in Central or Southern Europe, and hospital overhead charges at Danish university hospitals are substantial. Per-patient costs for a Phase II oncology study typically range from €22,000 to €50,000.
Despite the high costs, Denmark’s data quality and fast regulatory process mean that the total cost of a Danish site contribution – accounting for quality, timeline, and the value of registry data – compares favourably when the programme benefits from Denmark’s particular strengths. Sponsors who include Denmark purely for enrolment volume, however, will find it poor value compared to Central European alternatives.
Denmark is an excellent choice when the programme values quality, speed, and data infrastructure over volume and cost. It is most appropriate when:
APICES provides full-service CRO support for clinical trials in Denmark, including CTIS regulatory submissions, DKMA and ethics committee liaison, site identification and feasibility, site management, and patient recruitment strategy. We understand the Danish registry landscape and can advise sponsors on integrating data access applications into their trial timelines.
For sponsors incorporating Denmark into a Scandinavian or pan-European programme, APICES provides integrated oversight across all participating countries. Our experience with Danish trial sites, including Rigshospitalet and Aarhus University Hospital, allows us to facilitate efficient contracting and initiation.
How long does clinical trial approval take in Denmark?
Denmark consistently delivers among the fastest clinical trial approval timelines in the EU. Under the EU CTR, all applications are submitted via CTIS and the DKMA conducts the Part I scientific and safety assessment in parallel with the ethics committee’s Part II review. For a complete, well-prepared dossier, both assessments typically conclude within 30–45 days from validation. RFI rates in Denmark are lower than the EU average, reflecting the DKMA’s efficient review process. Sponsors should still plan for the possibility of RFIs and prepare thorough dossiers to minimise the risk.
What are Denmark’s national health registries and why do they matter for clinical trials?
Denmark’s Civil Person Register (CPR) assigns a unique 10-digit identifier to every Danish resident, enabling cross-linkage across a comprehensive suite of national health registries. These include the Danish Cancer Registry, the National Patient Registry (covering all hospital contacts since 1977), the Danish Civil Registration System, the National Prescription Registry, the Cause of Death Registry, and numerous disease-specific registries. For clinical trials, this infrastructure enables registry-linked endpoints (e.g., OS, cancer incidence) without requiring additional patient contact, long-term safety follow-up of trial participants after study completion, and pre-screening of patient populations for trial eligibility. Access to registry data requires separate approval from the Danish Health Data Authority and relevant data stewards, and this process should be initiated in parallel with the CTIS submission.
Is Denmark expensive for clinical trials?
Yes – Denmark is one of the most expensive countries in Europe for clinical research. Scandinavian salary levels for research nurses, coordinators, and investigators are substantially higher than in Central or Southern Europe, and Danish university hospital overhead charges are significant. Per-patient costs for a Phase II oncology trial typically range from €22,000 to €50,000. Sponsors include Denmark for its fast approvals, high data quality, registry infrastructure, and investigator expertise rather than for cost advantages. For sponsors whose programmes genuinely benefit from these characteristics, the cost is often justified.
What are the main clinical trial sites in Denmark?
Rigshospitalet (Copenhagen University Hospital) is Denmark’s national reference hospital and most active trial site, with particular strength in oncology, haematology, and cardiovascular medicine. Aarhus University Hospital is the leading site in Jutland, with strong programmes in oncology, diabetes, and neuroscience. Odense University Hospital (OUH) serves the Funen and Southern Jutland region and is active in oncology and respiratory research. Herlev Hospital (part of the Copenhagen University Hospital group) is particularly strong in gastrointestinal and urological oncology.
Does Denmark use CTIS for clinical trial applications?
Yes. Denmark fully implements the EU Clinical Trials Regulation (EU CTR, Regulation EU 536/2014) and all interventional clinical trial applications are submitted via the Clinical Trials Information System (CTIS). The Danish Medicines Agency (DKMA) is the national competent authority. The National Committee on Health Research Ethics (NVK) coordinates the ethics review. Denmark can serve as either the Reporting Member State or a Member State Concerned in multi-country submissions.
Is Denmark suitable for rare disease clinical trials?
Denmark is disproportionately productive for rare disease research relative to its population size, primarily because of its registry infrastructure. The CPR-linked disease registries allow systematic identification of essentially all confirmed patients with a given rare condition in Denmark, making pre-screening highly efficient. Rigshospitalet and specialist departments at Aarhus University Hospital host the principal rare disease reference centres. Absolute patient numbers are capped by the population of 5.9 million, so Denmark works best as one site in a multinational rare disease programme rather than as the sole or primary country.
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
